AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31686823
Drug: Aripiprazole lauroxil
RxNorm normalized name: Aripiprazole lauroxil
DrugBank: Aripiprazole lauroxil (DB14185)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aripiprazole lauroxil (441 mg and 882 mg)
Trial: 31686823
Drug: Aripiprazole lauroxil
RxNorm normalized name: Aripiprazole lauroxil
DrugBank: Aripiprazole lauroxil (DB14185)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aripiprazole lauroxil (441 mg)
Trial: 31686823
Drug: Aripiprazole lauroxil
RxNorm normalized name: Aripiprazole lauroxil
DrugBank: Aripiprazole lauroxil (DB14185)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aripiprazole lauroxil (882 mg)
Trial: 31686823
Drug: Aripiprazole lauroxil
RxNorm normalized name: Aripiprazole lauroxil
DrugBank: Aripiprazole lauroxil (DB14185)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aripiprazole lauroxil (pooled doses)
Trial: 25178517
Drug: Ibrutinib 840
RxNorm normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ibrutinib 840 mg/day
Trial: 24054464
Drug: Switching to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switching to monotherapy
Trial: 21205110
Drug: Mg-aspartate-hydrochloride (n
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mg-aspartate-hydrochloride (n = 27)
Trial: 16648513
Drug: Locoregional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Locoregional therapy only
Trial: 11191541
Drug: Low-dose dopamine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose dopamine (2 microg kg(‐1) min(‐1))
Trial: 9170041
Drug: Saline flush
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline flush after contrast injection
Trial: 9170041
Drug: No saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No saline flush after contrast injection
Trial: 1331788
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 and calcium supplementation (1.2 g elemental calcium and 20 micrograms (800 IU) of vitamin D3 daily for 18 months)
Trial: 31755300
Drug: Customized meditation
RxNorm normalized name: benzalkonium chloride Topical Foam [Meditize]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Customized meditation program (weekly classes for 2 years)
Trial: 26908041
Drug: 2 %
RxNorm normalized name: oxygen 2 %
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 % carbohydrate (L-CHO) beverages
Trial: 26908041
Drug: 6 %
RxNorm normalized name: oxygen 96 %
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 % carbohydrate (H-CHO) solutions with 20 g protein
Trial: 17644545
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (other treatment strategies)
Trial: 16648739
Drug: OP‐1 Putty
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OP‐1 Putty (3.5 mg OP‐1/g of collagen matrix per side)
Trial: 14631136
Drug: ivabradine 0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ivabradine 0.25 mg/kg
Trial: 10725817
Drug: Interferential current
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferential current (IFC) treatment for palmar psoriasis
Trial: 10725817
Drug: Interferential current
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferential current (IFC) treatment
Trial: 8840370
Drug: Intramuscular fosphenytoin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular fosphenytoin (480-1500 mg loading doses, 130-1250 mg daily maintenance doses for 3-14 days)
Trial: 8840370
Drug: Intravenous fosphenytoin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous fosphenytoin (1082 +/- 299 mg loading doses, 411 +/- 221 mg daily maintenance doses for 3-14 days)
Trial: 8840370
Drug: Intravenous phenytoin
RxNorm normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous phenytoin sodium (1082 +/- 299 mg loading doses, 422 +/- 197 mg daily maintenance doses for 3-14 days)
Trial: 8840370
Drug: Both intravenous
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both intravenous fosphenytoin and phenytoin sodium
Trial: 6142005
Drug: Esmolol (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Esmolol (intravenous administration)
Trial: 27577513
Drug: Spectral CT
RxNorm normalized name: Sentinel Spectrum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spectral CT imaging (1 ml/kg contrast agent)
Trial: 27577513
Drug: Conventional CT
RxNorm normalized name: CT-179
DrugBank: CT-179 (DB17114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional CT imaging (120 kVp, 1 ml/kg contrast agent)
Trial: 17230596
Drug: Fingolimod 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fingolimod 1.25 mg orally
Trial: 17230596
Drug: Fingolimod 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fingolimod 1 mg intravenously infused over 2 h
Trial: 14705236
Drug: Alfacalcidol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfacalcidol (1 micro g/day) alone (alfacalcidol group, n = 11)
Trial: 14705236
Drug: Alfacalcidol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfacalcidol (1 micro g/day) and intermittent cyclical etidronate (200 mg/day for 14 days, given for 4 cycles) (combined group, n = 10)
Trial: 7665805
Drug: Bright-light therapy
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bright-light therapy
Trial: 7665805
Drug: Dim light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dim light (after bright-light therapy)
Trial: 7665805
Drug: Bright-light therapy
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bright-light therapy (control group)
Trial: 30818311
Drug: Topical sialagogue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical sialagogue spray containing malic acid 1% (SalivAktive®)
Trial: 11016777
Drug: iobitridol 300
RxNorm normalized name: iobitridol 300 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iobitridol 300 (low‐osmolar, 300 mg I/ml)
Trial: 11016777
Drug: iobitridol 350
RxNorm normalized name: iobitridol 350 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iobitridol 350 (low‐osmolar, 350 mg I/ml)
Trial: 11016777
Drug: ioxithalamate 350
RxNorm normalized name: meglumine ioxithalamate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ioxithalamate 350 (high‐osmolar, 350 mg I/ml)
Trial: 6703818
Drug: Intravenous verapamil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous verapamil hydrochloride (0.075 mg/kg and 0.15 mg/kg given 15 minutes apart)
Trial: 6703818
Drug: Intravenous verapamil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous verapamil hydrochloride
Trial: 30221330
Drug: Intravenous and
RxNorm normalized name: immune globulin intravenous and subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous and intra-articular TXA and RIV postoperatively (Group A)
Trial: 30221330
Drug: Intravenous and
RxNorm normalized name: immune globulin intravenous and subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous and intra-articular TXA and LMWH postoperatively (Group B)
Trial: 31584145
Drug: Budesonide-formoterol (ICS-LABA)
RxNorm normalized name: budesonide / formoterol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide-formoterol (ICS-LABA) as rescue medication
Trial: 31584145
Drug: ICS-LABA combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICS-LABA combination used as needed
Trial: 31584145
Drug: Chronic ICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chronic ICS treatment
Trial: 25740537
Drug: D2-receptor antagonist
RxNorm normalized name: vitamin D2
DrugBank: Ergocalciferol (DB00153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: D2-receptor antagonist amisulpride
Trial: 21489663
Drug: diet +
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: diet + PS (2 g/day)
Trial: 18577159
Drug: Basal insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Basal insulin (insulin glargine) added to existing oral therapy
Trial: 18577159
Drug: Rapid-acting insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid-acting insulin (insulin glulisine)
Trial: 18577159
Drug: Optimization of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimization of basal insulin dose with addition of prandial insulin
Trial: 18577159
Drug: Basal-bolus insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Basal-bolus insulin strategy
Trial: 18577159
Drug: Premixed insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Premixed insulin strategy
Trial: 17137975
Drug: Nonventing curette
RxNorm normalized name: desogestrel
DrugBank: Desogestrel (DB00304)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nonventing curette with pump settings of 5 mL/min and 10 mm Hg
Trial: 17137975
Drug: Venting curette
RxNorm normalized name: lidocaine hydrochloride Injectable Solution [Pro Vent Plus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venting curette with pump settings of 7 to 10 mL/min and 50 mm Hg
Trial: 3305620
Drug: Chlorhexidine-fluoride gel
RxNorm normalized name: chlorhexidine / sodium fluoride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorhexidine-fluoride gel
Trial: 23911560
Drug: Surgical staging
RxNorm normalized name: fluorexon stain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical staging via a minimally invasive extraperitoneal approach followed by tailored radiotherapy with chemotherapy
Trial: 23911560
Drug: Pelvic radiotherapy
RxNorm normalized name: Sus scrofa renal pelvis preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pelvic radiotherapy with chemotherapy (standard-of-care arm)
Trial: 11123451
Drug: Clotrimazole troche
RxNorm normalized name: Clotrimazole Troche
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clotrimazole troche (10 mg, five times daily)
Trial: 11123451
Drug: Itraconazole oral
RxNorm normalized name: itraconazole Oral Tablet
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Itraconazole oral solution (100 mg/10 mL, twice daily)
Trial: 3328853
Drug: Flupirtine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flupirtine (100 mg capsules and 150 mg suppositories)
Trial: 2757680
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg nifedipine preparation (test preparation)
Trial: 2757680
Drug: Marketed reference
RxNorm normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Marketed reference preparation (control)
Trial: 2757680
Drug: Both preparations
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both preparations (test and reference)
Trial: 31758926
Drug: Monthly 0.3‐mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly 0.3‐mg intravitreal ranibizumab injections
Trial: 29721714
Drug: Early oral
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early oral feeding after distal gastrectomy (DG)
Trial: 29721714
Drug: Early oral
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early oral feeding after total gastrectomy (TG)
Trial: 22658249
Drug: Sufentanil 1
RxNorm normalized name: SUFentanil 100 MCG in 2 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil 1 μg/kg plus Ropivacaine 0.5mg/kg
Trial: 22658249
Drug: Sufentanil 1
RxNorm normalized name: SUFentanil 100 MCG in 2 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil 1 μg/kg, Ropivacaine 0.5mg/kg plus Epinephrine 6 μg/kg
Trial: 18697911
Drug: High protein
RxNorm normalized name: Vital High Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High protein diet (HP; 3.0 g protein x kg fat‐free mass (FFM)(‐1) x day(‐1))
Trial: 18697911
Drug: Usual protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual protein intake (UP; 1.5 g protein x kg FFM(‐1) x day(‐1))
Trial: 9931535
Drug: Dexamethasone treatment
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone treatment for 3 days
Trial: 9931535
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment for 3 days
Trial: 7574816
Drug: Granisetron monotherapy
RxNorm normalized name: Granisetron
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Granisetron monotherapy (40 micrograms/kg)
Trial: 7574816
Drug: Granisetron plus
RxNorm normalized name: Granisetron
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Granisetron plus steroids (500 mg of methylprednisolone succinate or 8 mg of dexamethasone phosphate prior to granisetron)
Trial: 7574816
Drug: Granisetron plus
RxNorm normalized name: Granisetron
DrugBank: Granisetron (DB00889)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Granisetron plus steroids
Trial: 224831
Drug: Day treatment
RxNorm normalized name: Pharmacist Clotrimazole 3 Day Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day treatment plus drugs
Trial: 224831
Drug: Drugs alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drugs alone
Trial: 27810522
Drug: Restarting quadruple
RxNorm normalized name: levonorgestrel
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Restarting quadruple therapy
Trial: 27810522
Drug: Average treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Average treatment duration
Trial: 16459223
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E (500 mg daily) and Vitamin C (750 mg daily)
Trial: 15225192
Drug: Dydrogesterone 10
RxNorm normalized name: dydrogesterone 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dydrogesterone 10 mg/day (E + D group, n = 140)
Trial: 15225192
Drug: Medroxyprogesterone acetate
RxNorm normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medroxyprogesterone acetate 5 mg/day (E + P group, n = 139)
Trial: 26205910
Drug: Intervention using
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention using supplements to increase the intake of EPA and DHA for 12 months
Trial: 26205910
Drug: Intervention using
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention using supplements to increase the intake of EPA and DHA
Trial: 21921571
Drug: GH 33
RxNorm normalized name: FUSION PROTEIN OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG- .BETA.)-(118-145)-PEPTIDE (1-28) WITH HUMAN SOMATOTROPIN (GROWTH HORMONE, GH) (29-219) AND TWO TANDEM COPIES OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG-.BETA.)-(118-145)- PEPTIDE (220-247
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH 33 μg/kg/day
Trial: 21921571
Drug: GH 67
RxNorm normalized name: FUSION PROTEIN OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG- .BETA.)-(118-145)-PEPTIDE (1-28) WITH HUMAN SOMATOTROPIN (GROWTH HORMONE, GH) (29-219) AND TWO TANDEM COPIES OF HUMAN CHORIOGONADOTROPIN SUBUNIT .BETA. (CG-.BETA.)-(118-145)- PEPTIDE (220-247
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH 67 μg/kg/day
Trial: 17931758
Drug: Neoadjuvant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant treatment (radiochemotherapy)
Trial: 17931758
Drug: Adjuvant treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant treatment (surgery and postoperative radiation)
Trial: 12364988
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of PP and Reverse Trendelenburg (RT) during laparoscopic GBP
Trial: 12364988
Drug: Sequential compression
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential compression devices during PP and RT in laparoscopic GBP
Trial: 12364988
Drug: Sequential compression
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential compression devices during RT in open GBP
Trial: 8879892
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate 250 micrograms twice daily
Trial: 6344899
Drug: Sustained-release theophylline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release theophylline (Nuelin SA) 350 mg daily
Trial: 6344899
Drug: Sustained-release theophylline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release theophylline (Nuelin SA) 700 mg daily
Trial: 31243588
Drug: Triamcinolone hexacetonide
RxNorm normalized name: Triamcinolone Hexacetonide
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamcinolone hexacetonide (steroid)
Trial: 31243588
Drug: Triamcinolone hexacetonide
RxNorm normalized name: Triamcinolone Hexacetonide
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamcinolone hexacetonide plus tenoxicam (steroid plus tenoxicam)
Trial: 27461426
Drug: Asenapine (2.5-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asenapine (2.5-10 mg twice daily)
Trial: 18227782
Drug: Family psychoeducational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family psychoeducational treatment
Trial: 16002035
Drug: Memantine (10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Memantine (10, 20, or 30 mg)
Trial: 11591884
Drug: Whey protein
RxNorm normalized name: Whey protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey protein (W; 1.2 g/kg/day)
Trial: 11591884
Drug: Whey protein
RxNorm normalized name: Whey protein
DrugBank: Whey (DB18685)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whey protein and creatine monohydrate (WC; 0.1 g/kg/day)
Trial: 11591884
Drug: Placebo (P;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (P; 1.2 g/kg/day maltodextrin)
Trial: 2649319
Drug: 0.05 percent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 percent betamethasone dipropionate in optimized cream vehicle applied twice a day
Trial: 2649319
Drug: 0.05 percent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 percent betamethasone dipropionate in optimized cream vehicle applied once a day
Trial: 27835048
Drug: Furosemide 20
RxNorm normalized name: furosemide 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide 20 mg OD + nifedipine
Trial: 22612061
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose prophylaxis
Trial: 22612061
Drug: Additional dose
RxNorm normalized name: chromous chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Additional dose 12 hours after prophylaxis
Trial: 22612061
Drug: Prophylactic dose
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic dose until nephrostomy tube removal
Trial: 15347709
Drug: VEGF gene
RxNorm normalized name: rhuMAb-VEGF
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: VEGF gene therapy (naked plasmid DNA encoding for human VEGF165)
Trial: 15347709
Drug: Laser therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laser therapy (direct myocardial revascularization)
Trial: 9504354
Drug: Perindopril (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril (2 mg daily)
Trial: 9504354
Drug: Amlodipine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (2.5 mg daily)
Trial: 7519554
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous opioid
Trial: 3354411
Drug: Oral Lorcainide
RxNorm normalized name: tocainide Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Lorcainide
Trial: 3354411
Drug: Intravenous Lorcainide
RxNorm normalized name: lorcainide
DrugBank: Lorcainide (DB13653)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Lorcainide
Trial: 4335443
Drug: 25-hydroxycholecalciferol (16,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25-hydroxycholecalciferol (16,000 IU single oral dose)
Trial: 4335443
Drug: 25-hydroxycholecalciferol (varied
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25-hydroxycholecalciferol (varied doses)
Trial: 27488859
Drug: Prasugrel for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel for 6 weeks at loading/maintenance doses of 20/3.75 mg (Continued Group; n = 68)
Trial: 27488859
Drug: Prasugrel at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel at 20/3.75 mg for 2 weeks followed by clopidogrel at 75 mg for 4 weeks (Switched Group; n = 68)
Trial: 27488859
Drug: Prasugrel at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel at 20/3.75 mg for 2 weeks followed by clopidogrel at 75 mg for 4 weeks (Switched Group)
Trial: 25875843
Drug: 5 injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 injections of HIV‐DNA, 1000 μg total dose (3 Env and 2 Gag encoding plasmids)
Trial: 25875843
Drug: 2 injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 injections of combined HIV‐DNA pools, 600 μg total dose
Trial: 25875843
Drug: 2 injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 injections with separated pools of HIV‐DNA, 600 μg total dose
Trial: 22036862
Drug: Hemoporfin 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemoporfin 2.5 mg/kg